Treatment of allergic diseases during pregnancy
Abstract
Pregnant women often have an allergic disease. The treatment of allergic diseases in pregnancy does not differ much from the treatment in general population. More important is allergen avoidance and health education of pregnant woman. Double blind placebo controlled trials of the treatment of allergic diseases in pregnancy are extremely rare. Use of drugs that have been on the market for longer time is recommended, because there is more information available on the safety of these drugs. Drugs for local use are generally safer than systemic drugs. It is recommended that nasal decongestants should be avoided. Among antihistamines the drugs of choice are cetirizine and loratadine. Among inhaled corticosteroids the drug of choice is budesonide. The treatment of anaphylaxis is the same as in general population.Downloads
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
